Randomized comparison of once-daily ceftibuten and twice-daily clarithromycin in the treatment of acute exacerbation of chronic bronchitis

Infection

Volumn 26, Issue 1, 1998, Pages 68-75

  Ziering, W ^a   McElvaine, P ^b  

^a California Clinical Consultants   (United States)

^b NONE   (United States)

Author keywords

Acute Exacerbation; Cefixime; Chronic Bronchitis; Clarithromycin; Eradication Rate

Indexed keywords

CEFTIBUTEN; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN;

ACUTE DISEASE; ADULT; AGED; ARTICLE; BRONCHITIS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ADMINISTRATION; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; BRONCHITIS; CEPHALOSPORINS; CLARITHROMYCIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 0031608036     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/BF02768764     Document Type: Article

References (31)

1. Prager, K., Turczyn, K., Lancashire, J., Smith, S.: National Center for Health Statistics data line. Public Health Report. 1994 vol. 109, issue 5. pp. 713–714.
2. Reynolds, H. Y.: Chronic bronchitis and acute infectious exacerbations. In:Mandell, G. L., Bennett, J. E., Dolin, R., (eds.): Principles and practice of infectious diseases, 4th ed. Churchill Livingstone, New York 1995, pp. 608–612.
3. Anthionisen, N. R., Manfreda, J., Warren, C. P. W., Herschfield, E. S., Harding, G. K. M., Nelson, N. A.: Antibiotic therapy in acute exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 106 (1987), 196–204.
4. Neu, H. C., Chick, T. W.: Efficacy and safety of clarithromycin compared to cefixime as outpatient treatment of lower respiratory tract infections. Chest 104 (1993) 1393–1399. DOI: 10.1378/chest.104.5.1393
5. Elbashier, A. M., Al-Salem, A. H., Al-Jama, A. H., Khogali, A., Abusrair, H., Khot, A. P., Malik, A. G.: Bronchopulmonary infection due toMoraxella (Branhamella) catarrhalis at Qatif Central Hospital. Ann. Saudi Med. 12 (1992) 562–564.
6. Cazzola, M., Ariano, R., Gioia, V., Mancini, V., Rimoldi, R., Scala, G., Scoccia, S., Girbino, G.: Bacterial isolates and cigarette smoking in patients with chronic bronchitis: results from an Italian multicenter survey. Clin. Ther. 12 (1990) 105–117.
7. Bensch, G. W., Klaustermeyer, W. B., McCarty, J., Schworer, P. B., Taglietti, M. A.: Efficacy and safety of once-daily ceftibuten vs. twice-daily ciprofloxacin in the treatment of acute exacerbation of chronic bronchitis. Infect. Dis. Clin. Pract. 4 (2 Suppl.) (1995) S80-S87.
8. Hosie, J., Quinn, P., Smite, P., Sides, G.: A comparison of 5 days of dirithromycin and 7 days of clarithromycin in acute bacterial exacerbation of chronic bronchitis. J. Antimicrob. Chemother. 36 (1995) 173–183. DOI: 10.1093/jac/36.1.173
9. Verghese, A., Roberson, D., Kalbfleisch, J. H., Sarubbi, F.: Randomized comparative study of cefixime versus cephalexin in acute bacterial exacerbations of chronic bronchitis. Antimicrob. Agents Chemother. 34 (1990) 1041–1044.
10. Turk, D. C.: Clinical importance ofHaemophilus influenzae-1981. In:Sell, S. H., Wright, P. F. (eds.):Haemophilus influenzae: epidemiology, immunology and prevention of disease. Elsevier Science Publishing Co., New York 1982, pp. 3–9.
11. Chodosh, S.: Acute bacterial exacerbations in bronchitis and asthma. Am. J. Med. 82 (Suppl. 4A) (1987) 154–163.
12. Thabaut, A., Meyran, M., Sofer, L., Morand, A., Labia, R.: Interactions of ceftibuten with extended-spectrum beta-lactamases: a bacteriological and enzymatic analysis. Drugs Exp. Clin. Res. 20 (1994 49–54.)
13. Jones, R. N.: Antimicrobial activity and spectrum of ceftibuten (7432-S, SCH 39720): a review of United States and Canadian results. Diagn. Microbiol. Infect. Dis 14 (1991) 37–43. DOI: 10.1016/0732-8893(91)90088-W
14. Friedland, I. R., McCracken, G. H. Jr.: Management of infections caused by antibiotic-resistantStreptococcus pneunoniae. N. Engl. J. Med. 331 (1994) 377–382. DOI: 10.1056/NEJM199408113310607
15. Jones, R. N.: Ceftibuten: a review of antimicrobial activity, spectrum, and other microbiologic features. Pediatr. Infect. Dis. 14 (Suppl.) (1995) S77-S83.
16. Doern, G. V.:In vitro activity of ceftibuten againstHaemophilus influenzae andBranhamella catarrhalis. Diagn. Microbiol. Infect. Dis. 14 (1991) 75–77. DOI: 10.1016/0732-8893(91)90092-T
17. Jones, R. N., Barry, A. L., andThe Collaborative Antimicrobial Susceptibility Testing Group: Ceftibuten (7432-S, SCH 39720): comparative antimicrobial activity against 4735 clinical isolates, beta-lactamase stability, and broth microdilution quality control guidelines. Eur. J. Clin. Microbiol. Infect. Dis. 7 (1988) 802–807. DOI: 10.1007/BF01975055
18. Wise, R., Andrews, J. M., Ashby, J. P., Thornber, D.: Ceftibutenin-vitro activity against respiratory pathogens, β-lactamase stability and mechanism of action. J. Antimicrob. Chemother. 26 (1990) 209–213. DOI: 10.1093/jac/26.2.209
19. Shawar, R., LaRocco, M., Cleary, T. G.: Comparativein vitro activity of ceftibuten (Sch 39720) against bacterial enteropathogens. Antimicrob. Agents Chemother. 33 (1989) 781–784.
20. Bauernfeind, A.: Ceftibuten and bactericidal kinetics. Comparativein vitro activity againstEnterobacteriaceae producing extended spectrum β-lactamases. Diagn. Microbiol. Infect. Dis. 14 (1991) 89–92. DOI: 10.1016/0732-8893(91)90095-W
21. Hardy, D. J.: Extent and spectrum of the antimicrobial activity of clarithromycin. Pediatr. Infect. Dis. J. 12 (Suppl.) (1993) S99-S105.
22. Fraschini, F., Scaglione, F., Demartini, G.: Clarithromycin clinical pharmacokinetics. Clin. Pharmacokinet. 25 (1993) 189–204.
23. th ed. W. B. Sauders Company, Philadelphia (1992).
24. Kamumer, R. B., Ress, R.: Randomized comparative study of ceftibuten versus cefaclor in the treatment of acute lower respiratory tract infections. Diagn. Microbiol. Infect. Dis. 14 (1991) 101–105. DOI: 10.1016/0732-8893(91)90097-Y
25. Cockburn, J., Gibberd, R. W., Reid, A. L., Sanson-Fischer, R. W.: Determinants of non-compliance with short term antibiotic regimens. Br. Med. J. 295 (1987) 814–818. DOI: 10.1136/bmj.295.6602.814
26. Eraker, S., Kirscht, J. P., Becker, M. H.: Understanding and improving patient compliance. Ann. Intern. Med. 100 (1984) 258–268.
27. Eisen, S. A., Douglas, K. M., Woodward, R. S., Spitznagel, E., Przybeck, T. R.: The effect of prescribed daily dose frequency on patient medication compliance. Arch. Intern. Med. 150 (1990) 1881–1884. DOI: 10.1001/archinte.150.9.1881
28. Wandstrat, T. L., Kaplan, B.: Pharmacoeconomic impact of factors affecting compliance with antibiotic regimens in the treatment of otitis media. Pediatr. Infect. Dis. J. 16 (1997) S27-S29. DOI: 10.1097/00006454-199702001-00008
29. Perotta, R., McCabe, R., Rumans, L., Nolen, T.: Comparison of the efficacy and safety of ceftibuten and cefaclor in the treatment of acute bacterial bronchitis. Infect. Dis. Clin. Pract. 3 (1994) 270–276. DOI: 10.1097/00019048-199407000-00007
30. Elliott, M., Taglietti, M.: Ceftibuten in the treatment of acute exacerbations of chronic bronchitis (AECB). Poster presented at the 19th International Congress of Chemotherapy, July 16–21, 1995, Montreal, Quebec, Canada.
31. Bachand, R. T. Jr.: Comparative study of clarithromycin and ampicillin in the treatment of patients with acute bacterial exacerbations of chronic bronchitis. J. Antimicrob. Chemother. 27 (Suppl. A) (1991) 91–100.